In-Vitro Testing of Rituximab in Combination with 2-CdA on Different Lymphoma Infected Cell Lines
Liddane, Allison L.
MetadataShow full item record
Non-Hodgkin's Lymphoma (NHL) is the most common form of the lymphomas. Each form of lymphoma has different biological behaviors and characteristics. Rituximab (Rtxn) is the drug used most commonly in the treatment of NHL. Rtxn has been shown to improve patient's survival and delays the developing reoccurrence. Rituximab has been used alone and in the combination with other drugs, like 2cd-A. In previous studies, preformed by this lab, rituximab was tested in combination with 2cd-A in-vivo, and the outcomes were successful. This same combination was then tested invitro and did not have a positive result. It was assumed that the Rtxn drug would not work successfully in:-vitro. In this study we tested different lots of rituximab alone and in combination with 2-CdA oh three different cell lines; and discovered that different lots of rituximab (solo and in combination) are able to be effective on in-vitro lymphoma cells. Of the seven Rtxn lots that were tested, in all three cell lines the drugs used in combination with 2-CdA were more effective than when the drug was used alone. One lot of Rtxn was the most effective over a 96 hour time period when used in combination in all three cell lines. In future work the drugs and combinations that are effective invitro will be tested in-vivo in immune deficient mice in order to test if the drug treatment can withstand an in-vivo environment. Then, hopefully with successful results, there will be human trials.